Skip to main content
SpringerLink
Log in

Cardiovascular Disease Pharmacogenomics

  • Chapter
  • First Online:
Omics for Personalized Medicine

Abstract

Cardiovascular disease (CVD), commonly known as heart disease, is the leading cause of death all over the world. Nearly one in four deaths worldwide is attributed to CVD. Generally, CVD constitutes a number of overlapping structural and functional irregularities in the heart and blood vessels, which together constitute the cardiovascular system. Given this, the corresponding drugs also either can treat or prevent these overlapping conditions. Often, more than one drug is prescribed to treat a medical condition, since one medication alone cannot remedy the problem. High mortality and morbidity due to CVD automatically requires physicians to treat CVD aggressively, leading to adverse drug reactions. Still, some patients do not respond positively even if the strongest recommended drug dosage is administered. Research in the CVD field has demonstrated linkage between gene variation and the severity of diseases such as blood cholesterol level or blood pressure. Correspondingly, research over more than three decades has established the linkage of genetic variation with the efficacy of CVD treatment in the cohorts of different CVD disease types. In this chapter, recent advances in the field of cardiovascular pharmacogenetics and pharmacogenomics are summarized.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Armitage J (2007) The safety of statin in clinical practice. Lancet 370:1781–1790

    CAS  PubMed  Google Scholar 

  • Arnett DK, Davis BR, Ford CE, Boerwinkle E, Leiendecker-Foster C, Miller MB, Black H, Eckfeldt JH (2005) Pharmacogenetic association of the angiotensin converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (Gen-HAT) study. Circulation 111:3374–3383

    CAS  PubMed  Google Scholar 

  • Arnett DK, Claas SA, Glasser SP (2006) Pharmacogenetics of antihypertensive treatment. Vascul Pharmacol 44:107–118

    CAS  PubMed  Google Scholar 

  • Baigent C, Keech A, Kearney PM, Blackwell L, Buck G et al (2005) Cholesterol Treatment Trialists’ (CTT) collaborators. Lancet 366:1267–1278

    CAS  PubMed  Google Scholar 

  • Ballantyne CM (2003) Current and future aims of lipid-lowering therapy: changing paradigms and lessons from the Heart Protection Study on standards of efficacy and safety. Am J Cardiol 92:3K–9K

    CAS  PubMed  Google Scholar 

  • Beitelshees AL, Gong Y, Wang D, Schork NJ, Cooper-Dehoff RM, INVEST Investigators et al (2007) KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST). Pharmacogenet Genomics 17:719–729

    CAS  PubMed Central  PubMed  Google Scholar 

  • Beitelshees AL, Navare H, Wang D, Gong Y, Wessel J et al (2009) CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response. Circ Cardiovasc Genet 2(4):362–370

    CAS  PubMed Central  PubMed  Google Scholar 

  • Bejarano-Achache I, Levy L, Mlynarsky L, Bialer M, Muszkat M, Caraco Y (2012) Effects of CYP4F2 polymorphism on response to warfarin during induction phase: a prospective, open-label, observational cohort study. Clin Ther 34:811–823

    CAS  PubMed  Google Scholar 

  • Berthold HK, Laaksonen R, Lehtimäki T, Gylling H, Krone W, Gouni-Berthold I (2008) SREBP-1c gene polymorphism is associated with increased inhibition of cholesterol-absorption in response to ezetimibe treatment. Exp Clin Endocrinol Diabetes 116:262–267

    CAS  PubMed  Google Scholar 

  • Boekholdt SM, Agema WR, Peters RJ, Zwinderman AH, van der Wall EE et al (2003) Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation 107:2416–2421

    CAS  PubMed  Google Scholar 

  • Bozkurt O, de Boer A, Grobbee DE, de Leeuw PW, Kroon AA, Schiffers P, Klungel OH (2009 May) Variation in renin-angiotensin system and salt-sensitivity genes and the risk of diabetes mellitus associated with the use of thiazide diuretics. Am J Hypertens 22(5):545–551

    CAS  PubMed  Google Scholar 

  • Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA et al (2007) Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 5:2429–2436

    CAS  PubMed  Google Scholar 

  • Brautbar A, Virani SS, Belmont J, Nambi V, Jones PH, Ballantyne CM (2012) LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. J Lipid Res 53:556–560

    CAS  PubMed Central  PubMed  Google Scholar 

  • Bray PF, Cannon CP, Goldschmidt-Clermont P, Moyé LA, Pfeffer MA, Sacks FM, Braunwald E (2001) The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction. Am J Cardiol 88:347–352

    CAS  PubMed  Google Scholar 

  • Brugts JJ, Isaacs A, de Maat MP, Boersma E, van Duijn CM et al (2011) A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals. J Hypertens 29:509–519

    CAS  PubMed  Google Scholar 

  • Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M et al (2008) CYP4F2 genetic variant alters required warfarin dose. Blood 111:4106–4112

    CAS  PubMed Central  PubMed  Google Scholar 

  • Carlquist JF, Muhlestein JB, Horne BD, Hart NI, Bair TL, Molhuizen HO, Anderson JL (2003) The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease. Am Heart J 146:1007–1014

    CAS  PubMed  Google Scholar 

  • Cen HJ, Zeng WT, Leng XY, Huang M, Chen X (2010) CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement. Br J Clin Pharmacol 70:234–240

    CAS  PubMed Central  PubMed  Google Scholar 

  • Chapman N, Chang CL, Caulfield M, Dahlöf B, Feder G, Sever PS, Poulter NR (2011) Ethnic variations in lipid-lowering in response to a statin (EVIREST): a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Ethn Dis 21:150–157

    PubMed  Google Scholar 

  • Chasman DI, Posada D, Subrahmanyan L et al (2004) Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 291:2821–2827

    CAS  PubMed  Google Scholar 

  • Chasman DI, Giulianini F, MacFadyen J, Barratt BJ, Nyberg F, Ridker PM (2012) Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circ Cardiovasc Genet 5:257–264

    CAS  PubMed  Google Scholar 

  • Chien KL, Wang KC, Chen YC et al (2010) Common sequence variants in pharmacodynamics and pharmacokinetic pathway-related genes conferring LDL cholesterol response to statins. Pharmacogenomics 11:309–317

    CAS  PubMed  Google Scholar 

  • Collet JP, Hulot JS, Pena A, Villard E, Esteve JB et al (2009) Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373:309–317

    CAS  PubMed  Google Scholar 

  • Cuisset T, Morange PE, Alessi MC (2012) Recent advances in the pharmacogenetics of clopidogrel. Hum Genet 131:653–664

    CAS  PubMed  Google Scholar 

  • Cusi D, Barlassina C, Azzani T, Casari G, Citterio L et al (1997) Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension. Lancet 349:1353–1357

    CAS  PubMed  Google Scholar 

  • D’Ambrosio RL, D’Andrea G, Cappucci F, Chetta M, Di Perna P, Brancaccio V, Grandone E, Margaglione M (2004) Polymorphisms in factor II and factor VII genes modulate oral anticoagulation with warfarin. Haematologica 89:1510–1516

    PubMed  Google Scholar 

  • D’Andrea G, D’Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, Grandone E, Margaglione M (2005) A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105:645–649

    PubMed  Google Scholar 

  • Dörr M, Schmidt CO, Spielhagen T, Bornhorst A, Hentschel K (2010) β-blocker therapy and heart rate control during exercise testing in the general population: role of a common G-protein β-3 subunit variant. Pharmacogenomics 11:1209–1221

    PubMed Central  PubMed  Google Scholar 

  • El Din MS, Amin DG, Ragab SB, Ashour EE, Mohamed MH, Mohamed AM (2012) Frequency of VKORC1 (C1173T) and CYP2C9 genetic polymorphisms in Egyptians and their influence on warfarin maintenance dose: proposal for a new dosing regimen. Int J Lab Hematol 34:517–524

    PubMed  Google Scholar 

  • Epstein RS, Moyer TP, Aubert RE, O’Kane DJ, Xia F, Verbrugge RR, Gage BF, Teagarden JR (2010) Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol 55:2804–2812

    CAS  PubMed  Google Scholar 

  • Fan YM, Laaksonen R, Janatuinen T, Vesalainen R, Nuutila P, Knuuti J, Lehtimäki T (2001) Effects of pravastatin therapy on serum lipids and coronary reactivity are not associated with SREBP cleavage-activating protein polymorphism in healthy young men. Clin Genet 60:319–321

    CAS  PubMed  Google Scholar 

  • Fiegenbaum M, da Silveira FR, Van der Sand CR, Van der Sand LC, Ferreira ME, Pires RC, Hutz MH (2005a) The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther 78(5):551–558

    CAS  PubMed  Google Scholar 

  • Fiegenbaum M, Silveira FR, Van der Sand CR, Van der Sand LC, Ferreira ME, Pires RC, Hutz MH (2005b) Determinants of variable response to simvastatin treatment: the role of common variants of SCAP, SREBF-1a and SREBF-2 genes. Pharmacogenomics J 5:359–364

    CAS  PubMed  Google Scholar 

  • Filigheddu F, Reid JE, Troffa C, PinnaParpaglia P, Argiolas G, Testa A, Skolnick M, Glorioso N (2004) Genetic polymorphisms of the beta-adrenergic system: association with essential hypertension and response to beta-blockade. Pharmacogenomics J 4:154–160

    CAS  PubMed  Google Scholar 

  • Filigheddu F, Argiolas G, Degortes S, Zaninello R, Frau F, Pitzoi S, Bulla E, Bulla P, Troffa C, Glorioso N (2012) Haplotypes of the adrenergic system predict the blood pressure response to beta-blockers in women with essential hypertension. Pharmacogenomics 11:319–325

    Google Scholar 

  • Fontana P, Hulot JS, De Moerloose P, Gaussem P (2007) Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects. J Thromb Haemost 5:2153–2155

    CAS  PubMed  Google Scholar 

  • Frazier L, Turner ST, Schwartz GL, Chapman AB, Boerwinkle E (2004) Multilocus effects of the renin-angiotensin-aldosterone system genes on blood pressure response to a thiazide diuretic. Pharmacogenomics J 4:17–23

    CAS  PubMed  Google Scholar 

  • Freeman DJ, Samani NJ, Wilson V, McMahon AD, Braund PS, Cheng S, Caslake MJ, Packard CJ, Gaffney D (2003) A polymorphism of the cholesteryl ester transfer protein gene predicts cardiovascular events in non-smokers in the West of Scotland Coronary Prevention Study. Eur Heart J 2420:1833–1842

    Google Scholar 

  • Fu R, Sun YM, Su Y, Wu Y, Luan Y (2008) Effect of statin therapy on plasma high-density lipoprotein-cholesterol levels is modified by paraoxonase 1 in Chinese patients with coronary heart disease. Clin Exp Pharmacol Physiol 35:982–983

    CAS  PubMed  Google Scholar 

  • Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ et al (2008) Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 84:326–331

    CAS  PubMed Central  PubMed  Google Scholar 

  • Gandelman K, Fung GL, Messig M, Laskey R (2012) Systemic exposure to atorvastatin between Asian and Caucasian subjects: a combined analysis of 22 studies. Am J Ther 9:164–173

    Google Scholar 

  • Gaziano TA (2005) Cardiovascular disease in the developing world and its cost-effective management. Circulation 112:3547

    PubMed  Google Scholar 

  • Geisler T, Schaeffeler E, Dippon J, Winter S, Buse V, Bischofs C, Zuern C, Moerike K, Gawaz M, Schwab M (2008) Cytochrome P450 2C19 and non-genetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics 9:1251–1259

    CAS  PubMed  Google Scholar 

  • Glorioso N, Manunta P, Filigheddu F, Troffa C, Stella P et al (1999) The role of alpha-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study. Hypertension 34:649–654

    CAS  PubMed  Google Scholar 

  • Gonzalez-Conejero R, Rivera J, Corral J, Acuña C, Guerrero JA, Vicente V (2005) Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure? Stroke 36:276–280

    CAS  PubMed  Google Scholar 

  • Guzman EC, Hirata MH, Quintão EC, Hirata RD (2000) Association of the apolipoprotein B gene polymorphisms with cholesterol levels and response to fluvastatin in Brazilian individuals with high risk for coronary heart disease. Clin Chem Lab Med 38:731–736

    CAS  PubMed  Google Scholar 

  • Hannuksela ML, Liinamaa MJ, Kesäniemi YA, Savolainen MJ (1994) Relation of polymorphisms in the cholesteryl ester transfer protein gene to transfer protein activity and plasma lipoprotein levels in alcohol drinkers. Atherosclerosis 110:35–44

    CAS  PubMed  Google Scholar 

  • Harrap SB, Tzourio C, Cambien F, Poirier O, Raoux S, PROGRESS Collaborative Group et al (2003) The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition. Hypertension 42:297–303

    CAS  PubMed  Google Scholar 

  • Heidenreich PA, Trogdon JG, Khavjou OA et al (2011) Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 123:933–944

    PubMed  Google Scholar 

  • Heller DA, de Faire U, Pedersen NL et al (1993) Genetic and environmental influences on serum lipid levels in twins. N Engl J Med 328:1150–1156

    CAS  PubMed  Google Scholar 

  • Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srino-uanprachanh SL, Farin FM, Rettie AE (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287:1690–1698

    CAS  PubMed  Google Scholar 

  • Himbergen TM, van Tits LJ, Voorbij HA, de Graaf J, Stalenhoef AF, Roest M (2005) The effect of statin therapy on plasma high-density lipoprotein cholesterol levels is modified by paraoxonase-1 in patients with familial hypercholesterolaemia. J Intern Med 258:442–449

    CAS  PubMed  Google Scholar 

  • Hingorani AD, Jia H, Stevens PA, Hopper R, Dickerson JE, Brown MJ (1995) Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertens 13:1602–1609

    CAS  PubMed  Google Scholar 

  • Holloway JW, Yang IA, Ye S (2005) Variation in the toll-like receptor 4gene and susceptibility to myocardial infarction. Pharmacogenet Genomics 15:15–21

    CAS  PubMed  Google Scholar 

  • Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P, Gaussem P (2006) Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108:2244–2247

    CAS  PubMed  Google Scholar 

  • Igel M, Arnold KA, Niemi M, Hofmann U, Schwab M, Lütjohann D, von Bergmann K, Eichelbaum M, Kivistö KT (2006) Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid lowering efficacy of multiple-dose pravastatin. Clin Pharmacol Ther 79:419–426

    CAS  PubMed  Google Scholar 

  • Jiang X, Sheng HH, Lin G, Li J, Lu XZ, Cheng YL, Huang J, Xiao HS, Zhan YY (2007) Effect of renin-angiotensin-aldosterone system gene polymorphisms on blood pressure response to antihypertensive treatment. Chin Med J (Engl) 120:782–786

    CAS  Google Scholar 

  • Jiang XY, Zhang Q, Chen P, Li SY, Zhang NN, Chen XD, Wang GC, Wang HB, Zhuang MQ, Lu M (2012) CYP7A1 polymorphism influences the LDL cholesterol-lowering response to atorvastatin. J Clin Pharm Ther 37:719–723

    CAS  PubMed  Google Scholar 

  • Johnson JA (2012) Advancing management of hypertension through pharmacogenomics. Ann Med 44(Suppl 1):S17–S22

    CAS  PubMed Central  PubMed  Google Scholar 

  • Johnson JA, Burkley BM, Langaee TY, Clare-Salzler MJ, Klein TE, Altman RB (2012) Implementing personalized medicine: development of a cost-effective customized pharmacogenetics genotyping array. Clin Pharmacol Ther 92:437–439

    CAS  PubMed Central  PubMed  Google Scholar 

  • Kacevska M, Ivanov M, Ingelman-Sundberg M (2012) Epigenetic-dependent regulation of drug transport and metabolism: an update. Pharmacogenomics 13:1373–1385

    CAS  PubMed  Google Scholar 

  • Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ (2004) Polymorphisms in the multidrug resistance-1(MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner. Am J Cardiol 93:1046–1050

    CAS  PubMed  Google Scholar 

  • Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ (2005) A promoter polymorphism in cholesterol 7alphahydroxylase interacts with apolipoprotein E genotype in the LDL lowering response to atorvastatin. Atherosclerosis 180:407–415

    CAS  PubMed  Google Scholar 

  • Kardia SL, Sun YV, Hamon SC, Barkley RA, Boerwinkle E, Turner ST (2007) Interactions between the adducin 2 gene and antihypertensive drug therapies in determining blood pressure in people with hypertension. BMC Med Genet 8:61

    PubMed Central  PubMed  Google Scholar 

  • Keskitalo JE, Pasanen MK, Neuvonen PJ, Niemi M (2009) Different effects of the ABCG2 c.421C > A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics 10:1617–1624

    CAS  PubMed  Google Scholar 

  • Kimura R, Miyashita K, Kokubo Y, Akaiwa Y, Otsubo R et al (2007) Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res 120:181–186

    CAS  PubMed  Google Scholar 

  • Klerkx AH, Tanck MW, Kastelein JJ, Molhuizen HO, Jukema JW, Zwinderman AH, Kuivenhoven JA (2003) Haplotype analysis of the CETP gene: not TaqIB, but the closely linked -629C–>A polymorphism and a novel promoter variant are independently associated with CETP concentration. Hum Mol Genet 12:111–123

    CAS  PubMed  Google Scholar 

  • Klos KL, Kullo IJ (2007) Genetic determinants of HDL: monogenic disorders and contributions to variation. Curr Opin Cardiol 22:344–351

    PubMed  Google Scholar 

  • Krauss RM, Mangravite LM, Smith JD et al (2008) Variation in the 3-hydroxyl-3-methylglutarylcoenzyme a reductase gene is associated with racial differences in low density lipoprotein cholesterol response to simvastatin treatment. Circulation 117:1537–1544

    CAS  PubMed  Google Scholar 

  • Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijff P, McPherson R, Bruschke AV, Lie KI, Kastelein JJ (1998) The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med 338:86–93

    CAS  PubMed  Google Scholar 

  • Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman KP, Nyström F, Hägg A, Lind L (2001) Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J Hypertens 19(10):1783–1787

    CAS  PubMed  Google Scholar 

  • Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman P, Nyström F, Hägg A, Lind L (2002) Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. J Hypertens 20:657–663

    CAS  PubMed  Google Scholar 

  • Kurland L, Liljedahl U, Karlsson J, Kahan T, Malmqvist K, Melhus H, Syvänen AC, Lind L (2004) Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. Am J Hypertens 17:8–13

    CAS  PubMed  Google Scholar 

  • Lahoz C, Peña R, Mostaza JM, Jiménez J, Subirats E, Pintó X, Taboada M, López-Pastor A, RAP Study Group (2003) Apo A-I promoter polymorphism influences basal HDL-cholesterol and its response to pravastatin therapy. Atherosclerosis 168:289–295

    CAS  PubMed  Google Scholar 

  • Lahoz C, Peña R, Mostaza JM, Laguna F, García-Iglesias MF, Taboada M, Pintó X (2005a) Baseline levels of low-density lipoprotein cholesterol and lipoprotein (a) and the AvaII polymorphism of the low-density lipoprotein receptor gene influence the response of low-density lipoprotein cholesterol to pravastatin treatment. Metabolism 54:741–747

    CAS  PubMed  Google Scholar 

  • Lahoz C, Peña R, Mostaza JM, Laguna F, García-Iglesias MF, Taboada M, Pintó X, RAP Study Group (2005b) The -514C/T polymorphism of the hepatic lipase gene significantly modulates the HDL-cholesterol response to statin treatment. Atherosclerosis 182(1):129–134, Epub 26 Feb 2005

    CAS  PubMed  Google Scholar 

  • Lanzani C, Citterio L, Glorioso N, Manunta P, Tripodi G et al (2010) Adducin- and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin, part 2: clinical studies. Sci Transl Med 2(59):ra87

    Google Scholar 

  • Law M, Wald N, Morris J (2003) Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technol Assess 7:1–94

    CAS  PubMed  Google Scholar 

  • Lev EI, Patel RT, Guthikonda S, Lopez D, Bray PF, Kleiman NS (2007) Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel. Thromb Res 119:355–360

    CAS  PubMed  Google Scholar 

  • Levitt MR, Osbun JW, Kim LJ (2012) The pharmacogenomics of clopidogrel. World Neurosurg 77:406–407

    PubMed  Google Scholar 

  • Li Y, Zhou Y, Yang P, Niu JQ, Wu Y, Zhao DD, Wu SL (2011) Interaction of ACE and CYP11B2 genes on blood pressure response to hydrochlorothiazide in Han Chinese hypertensive patients. Clin Exp Hypertens 33:141–146

    CAS  PubMed  Google Scholar 

  • Liu J, Liu ZQ, Tan ZR, Chen XP, Wang LS, Zhou G, Zhou HH (2003) Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin Pharmacol Ther 74:372–379

    CAS  PubMed  Google Scholar 

  • Liu J, Liu ZQ, Yu BN, Xu FH, Mo W, Zhou G, Liu YZ, Li Q, Zhou HH (2006) Beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. Clin Pharmacol Ther 80:23–32

    CAS  PubMed  Google Scholar 

  • Lubitz SA, Scott SA, Rothlauf EB, Agarwal A, Peter I et al (2010) Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. J Thromb Haemost 8:1018–1026

    CAS  PubMed  Google Scholar 

  • Luo F, Wang Y, Wang X, Sun K, Zhou X, Hui R (2009) A functional variant of NEDD4L is associated with hypertension, antihypertensive response, and orthostatic hypotension. Hypertension 54:796–801

    CAS  PubMed  Google Scholar 

  • Ma C, Zhang Y, Xu Q, Yang J, Zhang Y, Gao L, Xu B, Wang H, Li Y, Lu C, Yin T (2012) Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin. Int J Hematol 96(6):719–728

    CAS  PubMed  Google Scholar 

  • Maitland-van der Zee AH, Klungel OH, Leufkens HG, de Boer A, Stricker BH, Hofman A, Witteman JC, van Duijn CM, Kastelein JJ (2004) Effectiveness of HMG-CoA reductase inhibitors is modified by the ACE insertion deletion polymorphism. Atherosclerosis 175:377–379

    CAS  PubMed  Google Scholar 

  • Maitland-van der Zee AH, Boerwinkle E, Arnett DK, Davis BR, Leiendecker-Foster C, Miller MB, Klungel OH, Ford CE, Eckfeldt JH (2007) Absence of an interaction between the angiotensin converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Am Heart J 153:54–58

    CAS  PubMed Central  PubMed  Google Scholar 

  • Malin R et al (2001) Paraoxonase genotype modifies the effect of pravastatin on high-density lipoprotein cholesterol. Pharmacogenetics 11(7):625–633

    CAS  PubMed  Google Scholar 

  • Mangravite LM, Thorn CF, Krauss RM (2006) Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J 6:360–374

    CAS  PubMed  Google Scholar 

  • Mangravite LM, Medina MW, Cui J, Pressman S, Smith JD, Rieder MJ, Guo X, Nickerson DA, Rotter JI, Krauss RM (2010) Combined influence of LDLR and HMGCR sequence variation on lipid-lowering response to simvastatin. Arterioscler Thromb Vasc Biol 30:1485–1492

    CAS  PubMed Central  PubMed  Google Scholar 

  • Manunta P, Lavery G, Lanzani C, Braund PS, Simonini M, Bodycote C, Zagato L, Delli Carpini S, Tantardini C, Brioni E, Bianchi G, Samani NJ (2008) Physiological interaction between alpha-adducin and WNK1-NEDD4L pathways on sodium-related blood pressure regulation. Hypertension 52:366

    CAS  PubMed  Google Scholar 

  • Maree AO, Curtin RJ, Chubb A, Dolan C, Cox D, O’Brien J, Crean P, Shields DC, Fitzgerald DJ (2005) Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost 3:2340–2345

    CAS  PubMed  Google Scholar 

  • Marian AJ, Safavi F, Ferlic L, Dunn JK, Gotto AM, Ballantyne CM (2003) Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study. J Am Coll Cardiol 35:89–95

    Google Scholar 

  • Marschang P, Sandhofer A, Ritsch A, Fiŝer I, Kvas E, Patsch JR (2006) Plasma cholesteryl ester transfer protein concentrations predict cardiovascular events in patients with coronary artery disease treated with pravastatin. J Intern Med 260:151–159

    CAS  PubMed  Google Scholar 

  • Mason DA, Moore JD, Green SA, Liggett SB (1999) A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem 274:12670–12674

    CAS  PubMed  Google Scholar 

  • Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED et al (1993) Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 328:914–921. Erratum in: N Engl J Med 330:1689, 1994

    Google Scholar 

  • Medina MW (2010) The relationship between HMGCR genetic variation, alternative splicing, and statin efficacy. Discov Med 9:495–499

    PubMed  Google Scholar 

  • Medina MW, Krauss RM (2009) The role of HMGCR alternative splicing in statin efficacy. Trends Cardiovasc Med 19:173–177

    CAS  PubMed Central  PubMed  Google Scholar 

  • Miniño AM, Murphy SL, Xu J, Kochanek KD (2011) Deaths: final data for 2008. National vital statistics reports, vol 59, no 10. National Center for Health Statistics, Hyattsville

    Google Scholar 

  • Mohrschladt MF, van der Sman-de Beer F, Hofman MK, van der Krabben M, Westendorp RG, Smelt AH (2005) TaqIB polymorphism in CETP gene: the influence on incidence of cardiovascular disease in statin-treated patients with familial hypercholesterolemia. Eur J Hum Genet 13:877–882

    CAS  PubMed  Google Scholar 

  • Motovska Z, Kvasnicka J, Hajkova J, Kala P, Simek S et al (2010) Platelet gene polymorphisms and risk of bleeding in patients undergoing elective coronary angiography: a genetic substudy of the PRAGUE-8 trial. Atherosclerosis 212:548–552

    CAS  PubMed  Google Scholar 

  • Musunuru K, Roden DM, Boineau R, Bristow MR, McCaffrey TA et al (2012) Cardiovascular pharmacogenomics: current status and future directions-report of a national heart, lung, and blood institute working group. J Am Heart Assoc 1:e000554

    PubMed Central  PubMed  Google Scholar 

  • Ned RM, Yesupriya A, Imperatore G, Smelser DT, Moonesinghe R, Chang MH, Dowling NF (2012) The ACE I/D polymorphism in US adults: limited evidence of association with hypertension-related traits and sex-specific effects by race/ethnicity. Am J Hypertens 25:209–215

    CAS  PubMed  Google Scholar 

  • Nestel P, Simons L, Barter P, Clifton P, Colquhoun D, Hamilton-Craig I, Sikaris K, Sullivan D (1997) A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin. Atherosclerosis 129:231–239

    CAS  PubMed  Google Scholar 

  • Niemi M (2007) Role of OATP transporters in disposition of drugs. Pharmacogenomics 8:787–802

    CAS  PubMed  Google Scholar 

  • Niemi M (2010) Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther 87:130–133

    CAS  PubMed  Google Scholar 

  • Niemi M, Neuvonen PJ, Hofmann U, Backman JT, Schwab M, Lütjohann D, von Bergmann K, Eichelbaum M, Kivistö KT (2005) Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype*17. Pharmacogenet Genomics 15:303–309

    CAS  PubMed  Google Scholar 

  • Niemi M, Pasanen MK, Neuvonen PJ (2011) Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 63:157–181

    CAS  PubMed  Google Scholar 

  • Niu Y, Gong Y, Langaee TY, Davis HM, Elewa H et al (2010) Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES). Circ Cardiovasc Genet 3:548–555

    CAS  PubMed Central  PubMed  Google Scholar 

  • Nurden AT (1997) Platelet glycoprotein IIIa polymorphism and coronary thrombosis. Lancet 350:1189–1191

    CAS  PubMed  Google Scholar 

  • Ojala JP, Helve E, Ehnholm C, Aalto-Setälä K, Kontula KK, Tikkanen MJ (1991) Effect of apolipoprotein E polymorphism and XbaI polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia. J Intern Med 230:397–405

    CAS  PubMed  Google Scholar 

  • Ordovas JM, Lopez-Miranda J, Perez-Jimenez F, Rodriguez C, Park JS, Cole T, Schaefer EJ (1995) Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis 113:157–166

    CAS  PubMed  Google Scholar 

  • Pamukcu B, Oflaz H, Nisanci Y (2005) The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis. Am Heart J 149:675–680

    CAS  PubMed  Google Scholar 

  • Pedro-Botet J, Schaefer EJ, Bakker-Arkema RG, Black DM, Stein EM, Corella D, Ordovas JM (2001) Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis 158:183–193

    CAS  PubMed  Google Scholar 

  • Pena R, Lahoz C, Mostaza JM, Jiménez J, Subirats E, Pintó X, Taboada M, López-Pastor A, Rap Study Group (2002) Effect of apoE genotype on the hypolipidaemic response to pravastatin in an outpatient setting. J Intern Med 251:518–525

    CAS  PubMed  Google Scholar 

  • Peters BJ, Rodin AS, Klungel OH, van Duijn CM, Stricker BH, Van’t Slot R, de Boer A, Maitland-van der Zee AH (2010) Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction. Pharmacogenomics 11:1065–1076

    CAS  PubMed  Google Scholar 

  • Peters BJ, Pett H, Klungel OH, Stricker BH, Psaty BM, Glazer NL, Wiggins KL, Bis JC, de Boer A, Maitland-van der Zee AH (2011) Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MI. Atherosclerosis 217:458–464

    CAS  PubMed Central  PubMed  Google Scholar 

  • Petersen M, Andersen JT, Jimenez-Solem E, Broedbaek K, Hjelvang BR et al (2012) Effect of the Arg389Glyβ(1)-adrenoceptor polymorphism on plasma renin activity and heart rate, and the genotype-dependent response to metoprolol treatment. Clin Exp Pharmacol Physiol 39:779–785

    CAS  PubMed  Google Scholar 

  • Pisciotta L, Sallo R, Rabacchi C, Wunsch A, Calandra S, Bertolini S (2012) Leucine 10 allelic variant in signal peptide of PCSK9 increases the LDL cholesterol-lowering effect of statins in patients with familial hypercholesterolaemia. Nutr Metab Cardiovasc Dis 22:831–835

    CAS  PubMed  Google Scholar 

  • Rau T, Düngen HD, Edelmann F, Waagstein F, Lainščak M, Dimković S et al (2012) Impact of the β1-adrenoceptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients. Clin Pharmacol Ther 92:21–28. Erratum in: Clin Pharmacol Ther 92:397, 2012

    Google Scholar 

  • Reitsma PH, van der Heijden JF, Groot AP, Rosendaal FR, Büller HR (2005) A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med 2:e312

    PubMed Central  PubMed  Google Scholar 

  • Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352:2285–2293

    CAS  PubMed  Google Scholar 

  • Rodrigues AC, Rebecchi IM, Bertolami MC, Faludi AA, Hirata MH, Hirata RD (2005) High baseline serum total and LDL cholesterol levels are associated with MDR1 haplotypes in Brazilian hypercholesterolemic individuals of European descent. Braz J Med Biol Res 38:1389–1397

    CAS  PubMed  Google Scholar 

  • Romaine SP, Bailey KM, Hall AS, Balmforth AJ (2010) The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J 10:1–11

    CAS  PubMed  Google Scholar 

  • Salazar LA, Hirata MH, Quintão EC, Hirata RD (2000) Lipid-lowering response of the HMG-CoA reductase inhibitor fluvastatin is influenced by polymorphisms in the low-density lipoprotein receptor gene in Brazilian patients with primary hypercholesterolemia. J Clin Lab Anal 14:125–131

    CAS  PubMed  Google Scholar 

  • Salek L, Lutucuta S, Ballantyne CM, Gotto AM Jr, Marian AJ (2002) Effects of SREBF-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatin. J Mol Med (Berl) 80:737–744

    CAS  Google Scholar 

  • Sanderson S, Emery J, Higgins J (2005) CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med 7:97–104

    CAS  PubMed  Google Scholar 

  • Sanllehy C, Casals E, Rodriguez-Villar C, Zambón D, Ojuel J, Ballesta AM, Ros E (1998) Lack of interaction of apolipoprotein E phenotype with the lipoprotein response to lovastatin or gemfibrozil in patients with primary hypercholesterolemia. Metabolism 47:560–565

    CAS  PubMed  Google Scholar 

  • Santos PC, Soares RA, Nascimento RM, Machado-Coelho GL, Mill JG, Krieger JE, Pereira AC (2011) SLCO1B1 rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a high risk ethnic group. BMC Med Genet 12:136

    CAS  PubMed Central  PubMed  Google Scholar 

  • Santos PC, Gagliardi AC, Miname MH, Chacra AP, Santos RD, Krieger JE, Pereira AC (2012) SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. Eur J Clin Pharmacol 68:273–279

    CAS  PubMed  Google Scholar 

  • Schalekamp T, van Geest-Daalderop JH, de Vries-Goldschmeding H, Conemans J, Bernsen Mj M, de Boer A (2004) Acenocoumarol stabilization is delayed in CYP2C93 carriers. Clin Pharmacol Ther 75:394–402

    CAS  PubMed  Google Scholar 

  • Schelleman H, Stricker BH, Verschuren WM, de Boer A, Kroon AA, de Leeuw PW, Kromhout D, Klungel OH (2006) Interactions between five candidate genes and antihypertensive drug therapy on blood pressure. Pharmacogenomics J 6:22–26

    CAS  PubMed  Google Scholar 

  • Sciarrone MT, Stella P, Barlassina C, Manunta P, Lanzani C, Bianchi G, Cusi D (2003) ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy. Hypertension 41:398–403

    CAS  PubMed  Google Scholar 

  • Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106:2329–2333

    CAS  PubMed  Google Scholar 

  • Shiffman D, Trompet S, Louie JZ, Rowland CM, Catanese JJ et al (2012) Genome-wide study of gene variants associated with differential cardiovascular event reduction by pravastatin therapy. PLoS One 7:e38240

    CAS  PubMed Central  PubMed  Google Scholar 

  • Shikata E, Ieiri I, Ishiguro S, Aono H, Inoue K, Koide T, Ohgi S, Otsubo K (2004) Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood 103:2630–2635

    CAS  PubMed  Google Scholar 

  • Sing K, Ballantyne CM, Ferlic L, Brugada R, Cushman I, Dunn JK, Herd JA, Pownall HJ, Gotto AM, Marian AJ (1999) Lipoprotein lipase gene mutations, plasma lipid levels, progression/regression of coronary atherosclerosis, response to therapy, and future clinical events. Lipoproteins and Coronary Atherosclerosis Study. Atherosclerosis 144:435–442

    CAS  PubMed  Google Scholar 

  • Singer JB, Holdaas H, Jardine AG, Fellstrøm B, Os I et al (2007) Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. J Lipid Res 48:2072–2078

    CAS  PubMed  Google Scholar 

  • Sofowora GG, Dishy V, Muszkat M, Xie HG et al (2003) A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade. Clin Pharmacol Ther 73:366–371

    CAS  PubMed  Google Scholar 

  • Sorkin SC, Forestiero FJ, Hirata MH, Guzmán EC, Cavalli SA, Bertolami MC, Salazar LA, Hirata RD (2005) APOA1 polymorphisms are associated with variations in serum triglyceride concentrations in hypercholesterolemic individuals. Clin Chem Lab Med 43:1339–1345

    CAS  PubMed  Google Scholar 

  • Sortica VA, Fiegenbaum M, Lima LO, Van der Sand CR, Van der Sand LC, Ferreira ME, Pires RC, Hutz MH (2012) SLCO1B1 gene variability influences lipid-lowering efficacy on simvastatin therapy in Southern Brazilians. Clin Chem Lab Med 50:441–448

    CAS  PubMed  Google Scholar 

  • Srivastava K, Chandra S, Bhatia J, Narang R, Saluja D (2012) Association of angiotensinogen (M235T) gene polymorphism with blood pressure lowering response to angiotensin converting enzyme inhibitor (Enalapril). J Pharm Pharm Sci 15(3):399–406

    CAS  PubMed  Google Scholar 

  • Stavroulakis GA, Makris TK, Krespi PG, Hatzizacharias AN, Gialeraki AE, Anastasiadis G, Triposkiadis P, Kyriakidis M (2000) Predicting response to chronic antihypertensive treatment with fosinopril: the role of angiotensin-converting enzyme gene polymorphism. Cardiovasc Drugs Ther 14:427–432

    CAS  PubMed  Google Scholar 

  • Superko HR, Momary KM, Li Y (2012) Statins personalized. Med Clin North Am 96:123–139

    CAS  PubMed  Google Scholar 

  • Svensson-Färbom P, Wahlstrand B, Almgren P, Dahlberg J, Fava C, Kjeldsen S, Hedner T, Melander O (2011) A functional variant of the NEDD4L gene is associated with beneficial treatment response with β-blockers and diuretics in hypertensive patients. J Hypertens 29:388–395

    PubMed  Google Scholar 

  • Tachibana-Iimori R, Tabara Y, Kusuhara H, Kohara K, Kawamoto R, Nakura J, Tokunaga K, Kondo I, Sugiyama Y, Miki T (2004) Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab Pharmacokinet 19:375–380

    CAS  PubMed  Google Scholar 

  • Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD et al (2006) Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese. Caucasians and African-Americans. Pharmacogenet Genomics 16:101–110

    CAS  PubMed  Google Scholar 

  • Takane H, Miyata M, Burioka N, Shigemasa C, Shimizu E, Otsubo K, Ieiri I (2006) Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy. J Hum Genet 51:822–826

    CAS  PubMed  Google Scholar 

  • Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N et al (2009) A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 5:e1000433

    PubMed Central  PubMed  Google Scholar 

  • Takeuchi F, Yamamoto K, Katsuya T, Sugiyama T, Nabika T et al (2012) Reevaluation of the association of seven candidate genes with blood pressure and hypertension: a replication study and meta-analysis with a larger sample size. Hypertens Res 35:825–831

    CAS  PubMed  Google Scholar 

  • Thompson JF, Man M, Johnson KJ et al (2005) An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J 5:352–358

    CAS  PubMed  Google Scholar 

  • Thompson JF, Hyde CL, Wood LS et al (2009) Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the treating to new targets (TNT) cohort. Circ Cardiovasc Genet 2:173–181

    CAS  PubMed  Google Scholar 

  • Turban S, Fuentes F, Ferlic L, Brugada R, Gotto AM, Ballantyne CM, Marian AJ (2001) A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin. Atherosclerosis 154:633–640

    CAS  PubMed  Google Scholar 

  • Turner ST, Schwartz GL, Chapman AB, Boerwinkle E (2001) C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic. Hypertension 37:739–743

    CAS  PubMed  Google Scholar 

  • Undas A, Sanak M, Musial J, Szczeklik A (1999) Platelet glycoprotein IIIa polymorphism, aspirin, and thrombin generation. Lancet 353:982–983

    CAS  PubMed  Google Scholar 

  • vanVenrooij FV, Stolk RP, Banga JD, Sijmonsma TP, van Tol A, Erkelens DW, Dallinga-Thie GM, DALI Study Group (2003) Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type2 diabetes. Diabetes Care 26:1216–1223

    CAS  Google Scholar 

  • Visser LE, van Schaik RH, van Vliet M, Trienekens PH, De Smet PA, Vulto AG, Hofman A, van Duijn CM, Stricker BH (2004) The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Thromb Haemost 92:61–66

    CAS  PubMed  Google Scholar 

  • Voora D, Shah SH, Reed CR, Zhai J, Crosslin DR et al (2008) Pharmacogenetic predictors of statin mediated low-density lipoprotein cholesterol reduction and dose response. Circ Cardiovasc Genet 1:100–106

    CAS  PubMed Central  PubMed  Google Scholar 

  • Vrablík M, Hubáček JA, Dlouhá D, Lánská V, Rynekrová J, Zlatohlávek L, Prusíková M, Ceška R, Adámková V (2012) Impact of variants within seven candidate genes on statin treatment efficacy. Physiol Res 61(6):609–617

    PubMed  Google Scholar 

  • Wadelius M, Pirmohamed M (2007) Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J 7:99–111

    CAS  PubMed  Google Scholar 

  • Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S, Holm L, McGinnis R, Rane A, Deloukas P (2009) The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113:784–792

    CAS  PubMed Central  PubMed  Google Scholar 

  • Winkelmann BR, Hoffmann MM, Nauck M, Kumar AM, Nandabalan K et al (2003) Haplotypes of the cholesteryl ester transfer protein gene predict lipid-modifying response to statin therapy. Pharmacogenomics J 3:284–296

    CAS  PubMed  Google Scholar 

  • Ye P, Shang Y, Ding X (2003) The influence of apolipoprotein B and E gene polymorphisms on the response to simvastatin therapy in patients with hyperlipidemia. Chin Med Sci J 18:9–13

    CAS  PubMed  Google Scholar 

  • Yuan HY, Chen JJ, Lee MT, Wung JC, Chen YF et al (2005) A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 14:1745–1751

    CAS  PubMed  Google Scholar 

  • Zhang X, Lynch AI, Davis BR, Ford CE, Boerwinkle E, Eckfeldt JH, Leiendecker-Foster C, Arnett DK (2012) Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study. PLoS One 7:e34217

    CAS  PubMed Central  PubMed  Google Scholar 

  • Zhou Y, Wu SL, Liu JQ, Liang WN, Liu GF (2007) Possible association of ACE gene I/D polymorphism with blood pressure–lowering response to hydrochlorothiazide. Biomed Environ Sci 20:351–356

    CAS  PubMed  Google Scholar 

  • Zuern CS, Schwab M, Gawaz M, Geisler T (2010) Platelet pharmacogenomics. J Thromb Haemost 8:1147–1158

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Molecular Cancer Pathology, National Institutes of Health, Building 10 Room 3B56, 10 Central Drive, Bethesda, MD, 20892-1500, USA

    Bishwanath Chatterjee

Authors
  1. Bishwanath Chatterjee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bishwanath Chatterjee .

Editor information

Editors and Affiliations

  1. Centre for Genomics & Applied Gene Technology, Institute of Integrative Omics and Applied Biotechnology (IIOAB), Purba Medinipur, West Bengal, India

    Debmalya Barh

  2. Institute of Life Sciences, B.V. Patel Pharmaceutical Education and Research Development Centre, Ahmedabad University, Ahmedabad, Gujarat, India

    Dipali Dhawan

  3. Policy Centre for Biomedical Research, Translational Health Science and Technology Institute (Department of Biotechnology Institute, Government of India), Office @ National Institute of Immunology, New Delhi, India

    Nirmal Kumar Ganguly

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer India

About this chapter

Cite this chapter

Chatterjee, B. (2013). Cardiovascular Disease Pharmacogenomics. In: Barh, D., Dhawan, D., Ganguly, N. (eds) Omics for Personalized Medicine. Springer, New Delhi. https://doi.org/10.1007/978-81-322-1184-6_20

Download citation

Publish with us

Policies and ethics

Search

Navigation